Fracture Risk in Prostate Cancer during Hormonal Therapy

摘要

Dear Editors, Men with prostate cancer are often at risk for other age-related adverse events, such as hip fractures. Osteoporosis is a common consequence of androgen deprivation therapy (ADT) for prostate cancer. Up to 20% of men treated with ADT suffer fractures within 5 years. It was previously believed that decreased sex hormone levels would induce the receptor activator of nuclear factor-kappa-B ligand in osteoblasts which consequently induced osteoclasts activate bone resorption. We retrospectively investigated the risk of fracture in prostate cancer patients treated with ADT. The institutional review board of Yokohama City University approved this study.